Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1CNS 1

Conditions

Pancreatic Neoplasms 4Rectal Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Testicular Neoplasms 1Testicular Germ Cell Tumor 1Teratoma, Testicular 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Salivary Gland Neoplasms 1Liver Neoplasms 1Head and Neck Neoplasms 1Esthesioneuroblastoma, Olfactory 1Carcinoma, Hepatocellular 1Cachexia 1

Interventions

Docetaxel 4Erlotinib Hydrochloride 3Cetuximab 3Radiotherapy 2Capecitabine 2tumor necrosis factor-alpha, CNGRC fusion protein, human 1tanespimycin 1sargramostim 1oncogene protein E7, Human papillomavirus type 16 1oblimersen 1entinostat 1aldesleukin 1X-Ray Therapy 1Thalidomide 1Ritonavir 1Phlebotomy 1Pemetrexed 1Nicotine 1Irinotecan 1Indinavir 1Immunologic Techniques 1Gemcitabine 1Fluorodeoxyglucose F18 1Filgrastim 1Fentanyl 1FPP(RGD)2 1Everolimus 1Epirubicin 1E6 protein, Human papillomavirus type 16 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esthesioneuroblastoma, Olfactory × Immunologic Techniques × Gastrointestinal × Clear all
NCT00896896 2013-04-02

Immunoreactivity to Cetuximab in Cancer Patients

Vanderbilt-Ingram Cancer Center

Completed
538 enrolled
CNSGastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Colonic Neoplasms, Head and Neck Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Colorectal Neoplasms, Esthesioneuroblastoma, Olfactory

Data powered by HemOnc (CC BY 4.0) Colophon âš¡